Atossa Genetics to Exhibit Its ForeCYTE Breast Health Test at the Breast Cancer Symposium 2013
(firmenpresse) - SEATTLE, WA -- (Marketwired) -- 09/06/13 -- (NASDAQ: ATOS), The Breast Health Company™, will display its at the 7th annual Breast Cancer Symposium from September 7 through September 9, 2013 in San Francisco. Atossa's exhibit will be located in Booth 33 at the San Francisco Marriott Marquis -- Golden Gate Hall.
The ForeCYTE Breast Health Test, developed and marketed by Atossa's subsidiary, , detects reversible precancerous conditions in the breast up to eight years before they become cancer. The test uses Atossa's that is quick, painless, and non-invasive and can be administered during an OB/GYN office visit. Unlike mammograms, which are commonly recommended for women starting at age 40 to 50, the ForeCYTE Breast Health Test is more age agnostic, uses no radiation and does not require invasive biopsy needles or surgical incisions. To view a video about the ForeCYTE Test, click here: .
"Our ForeCYTE Breast Health Test provides vital early detection of precancerous abnormalities that can lead to breast cancer over an approximately 8-year time frame," said Chris Destro, Vice President of Atossa. "By identifying women with precancerous abnormalities and empowering them with useful information, we can help women and their doctors to take important steps to reverse the condition through lifestyle changes and/or therapeutic intervention and thereby potentially prevent breast cancer and save lives. We look forward to presenting ForeCYTE's value at the Breast Cancer Symposium in San Francisco."
Atossa's ForeCYTE Breast Health Test is available through physicians nationwide.
Now in its 7th year, the Breast Cancer Symposium brings together medical and radiation oncologists as well as surgeons to focus on understanding and incorporating the latest research from each subspecialty, in order to strengthen collaborative treatment approaches and to enhance patient care.
Atossa, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, the NRLBH, patented, laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography.
The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.
For additional information on Atossa, please visit . For additional information on the ForeCYTE test and the NRLBH, please visit .
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Atossa Genetics, Inc.
Chris Destro
VP, Sales & Marketing
(O) 800-351-3902
MBS Value Partners
Matthew D. Haines
(Investors)
Managing Director
(O) 212-710-9686
JQA Partners
Jules Abraham
(Media)
Principal
(O) 917-885-7378
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.09.2013 - 06:30 Uhr
Sprache: Deutsch
News-ID 1261113
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SEATTLE, WA
Phone:
Kategorie:
Medical Devices
Anmerkungen:
Diese Pressemitteilung wurde bisher 207 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Atossa Genetics to Exhibit Its ForeCYTE Breast Health Test at the Breast Cancer Symposium 2013
"
steht unter der journalistisch-redaktionellen Verantwortung von
Atossa Genetics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
